Nexletol

Fresh off its first FDA approval, Esperion gets green light for second non-statin cholesterol drug

The FDA approved Nexlizet, according to an entry in its database of approved drugs. The new drug combines the active ingredient of Nexletol - which the FDA approved last week - with a generic non-statin drug, ezetimibe.

By Alaric DeArment

BioPharma

FDA approves Esperion’s non-statin cholesterol-lowering drug

The drug, Nexletol, is designed for use with maximally tolerated statins for lowering LDL cholesterol in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.

By Alaric DeArment